Abstract: Objective To explore the therapeutic effect and safety of bevacizumab combined with chemotherapy in previously treated advanced patients with non-small cell lung cancer （NSCLC）.
Methods In this study， 84 patients pathologically in accordance with the feature of advanced NSCLC were treated with bevacizumab combined with chemotherapy from May 2010 to July 2014. The curative effect was analyzed according to Response Evaluation Criteria in Solid Tumors （RECIST） 1.1 every 2 cycles. The National Cancer Institute Common Toxicity Criteria （NCI-CTC） version 3.0 was employed to evaluate the adverse reaction. Survival analysis was performed using Kaplan-Meier method. Results All the 84 patients were evaluable for response. There were no CR cases， 12 cases of PR， 42 cases of SD and 30 cases of PD with the response rate and disease control rate of 14.8% and 64.8%. The median progression free survival and overall survival were 3.8 months and 8.8 months， respectively. The main adverse reactions of bevacizumab were hypertension， bone marrow suppression, liver function damage and skin rash， manifested most as degree 1-2 but rarely degree 3-4. Conclusion It was effective and safe for advanced NSCLC patients treated with bevacizumab combined with chemotherapy.